A Promising New Immune Checkpoint from Sensei Bio: VISTA

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/40/74/2e/40742e6c-6a61-2d95-b634-8dda4a9dba7b/mza_13147460199252821216.jpg/600x600bb.jpg

LifeSci Partners Podcast

LifeSci Partners.com

74 episodes

1 week ago

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

Life Sciences

Science

RSS

All content for LifeSci Partners Podcast is the property of LifeSci Partners.com and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/12716813/12716813-1620938344168-d59435a1debe2.jpg

A Promising New Immune Checkpoint from Sensei Bio: VISTA

LifeSci Partners Podcast

33 minutes 29 seconds

2 years ago

A Promising New Immune Checkpoint from Sensei Bio: VISTA

CTLA-4 was a breakthrough; PD-1—a blockbuster, then IDO got busted and biotech retreated to the bench. It got quiet for a while, but the basic science bounced back, and now we have LAG-3, and on the horizon, a new VISTA. Myeloid cells have the target, and Sensei Bio has the drug. Tune in as CEO John Celebi tells us the story of SNS-101 and why the Fc component is so important.